Monitoring crustal changes at volcanoes by seismic noise interferometry: Mt. Etna case of study

In this work, we analysed the seismic noise recorded at Mt. Etna by 18 stations during the interval 2007–2015 in the frequency band 0.1–0.3 Hz, chosen to avoid contamination from volcanic tremor. Variations in time of medium seismic velocity in the range − 0.8 to 0.8% were found, mostly affecting the stations located on the volcano summit and flanks. Based on the investigated frequency content, the Δv/v changes took place from the surface to a depth of ~ 4.5–6.5 km. To identify the source mechanism of the observed medium changes, the variations were quantitatively compared by wavelet transform coherence with volcano-tectonic and meteorological parameters. A significant relationship with meteorological parameters with seasonal periodicity (especially air temperature and snow loading) was found, probably caused by thermo-elastic strain and increasing-decreasing surface loading cycles. Moreover, a sharp medium velocity decrease, taking place in mid-December 2009 and clearly time-related to the largest volcano-tectonic strain release phenomenon of the investigated period, was also found. Such a velocity decrease was interpreted as resulting from ascent of fluids and gas exsolution taking place at the same time as the volcano-tectonic swarm.Published165-1744V. Dinamica dei processi pre-eruttiviJCR Journa

Unravelling the Relationship Between Microseisms and Spatial Distribution of Sea Wave Height by Statistical and Machine Learning Approaches

Global warming is making extreme wave events more intense and frequent. Hence, the importance of monitoring the sea state for marine risk assessment and mitigation is increasing day-by-day. In this work, we exploit the ubiquitous seismic noise generated by energy transfer from the ocean to the solid earth (called microseisms) to infer the sea wave height data provided by hindcast maps. To this aim, we use a combined approach based on statistical analysis and machine learning. In particular, a random forest model shows very promising results in the spatial and temporal reconstruction of sea wave height by microseisms. The observed dependence of input importance from the distance sea grid cell-seismic station suggests how the reliable monitoring of the sea state in a wide area by microseisms needs data recorded by dense networks, comprising stations evenly distributed along the coastlines

Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry.

OBJECTIVE: To determine whether characteristics and outcomes of Italian patients in the observational global Hypopituitary Control and Complication Study (HypoCCS) differed according to the degree of GH deficiency (GHD). DESIGN:Patients were grouped by tertiles of stimulated GH peak concentration at baseline (Group A lowest tertile, n = 342; Group B middle tertile, n = 345; Group C highest tertile, n = 338). RESULTS: Baseline demographics, lipid levels, body mass index categories and mean Framingham cardiovascular risk indexes were similar in the three groups and remained substantially unchanged over time, with no subsequent significant between-group differences (except mean levels of triglycerides increased in the highest tertile group). GHD was adult-onset for >75% of patients in all groups. The percentage of patients with multiple pituitary deficiencies was higher in Group A than in the other groups; isolated GHD was reported with highest frequency in Group C. Patients in Group A received the lowest mean starting dose of GH. Hyperlipidaemia at baseline was reported in 35·1%, 31·1% and 24·7% of patients in groups A, B and C, respectively (P = 0·029). Mean duration of GH treatment was 7·21, 5·45 and 4·96 years, respectively. The proportion of patients with adverse events did not differ significantly between groups, with a low prevalence over time of diabetes and cancer. CONCLUSIONS: In Italian patients from HypoCCS, the level of GH deficit did not influence changes over time in metabolic parameters or adverse event profile, despite differences in GHD severity at baseline and in the starting GH dose

Analisi del trattamento con ormone della crescita umano (GH) in base alla durata della terapia nei pazienti italiani dello studio HYPOCCS (Hypopituitary Control and Complication Study)

Results of the HYPOCCS Study focusing on the role of the duration of r-hGH treatment on several parameter

Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014

Purpose: Somatropin [recombinant growth hormone (rGH)] is approved in children and adults for several conditions involving growth disturbances and the corresponding biosimilar is available in Italy since 2006. No population-based data are available on the pattern of rGH use in Italian clinical practice. This study aimed at exploring the pattern of biosimilar and originator rGH use in six Italian centers, where different policy interventions promoted biosimilar use. Methods: This population-based, drug-utilization study was conducted in the years 2009-2014, using administrative databases of Umbria, Tuscany, and Lazio Regions and Local Health Units of Caserta, Treviso, and Palermo. Naive rGH users were characterized, and prevalence of use and discontinuation were assessed over time. Results: Among 6,785 patients treated with rGH during the study years, 4,493 (66.2%) were naive users (males/females = 1.3), mostly affected by GH deficiency. The prevalence of rGH use increased from 2009 to 2010, remaining stable thereafter, but it was heterogeneous across centers (twofold higher prevalence of use in center n.2 than centers n.4 and 1 in 2014). Biosimilar rGH uptake increased over time but was low (7.8% in 2014) and heterogeneous as well. Discontinuation of rGH therapy occurred in 54.0% of naive users, more frequently in females than males (58.1 vs. 50.9%). During the first year of treatment, discontinuation was frequent (39.9%), but no statistically significant differences were observed in treatment persistence for biosimilar vs. originator rGH (p > 0.05). Conclusion: Geographical heterogeneity in the prevalence of rGH use was observed. Similary, the biosimilar rGH uptake was and variable across centers. post-marketing monitoring is required to continuously monitor the benefit-risk profile of rGH, thus guaranteeing greater savings than only promoting lowest cost rGH

Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study.

CONTEXT: Traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) are conditions at high risk for the development of hypopituitarism. OBJECTIVE: The objective of the study was to clarify whether pituitary deficiencies and normal pituitary function recorded at 3 months would improve or worsen at 12 months after the brain injury. DESIGN AND PATIENTS: Pituitary function was tested at 3 and 12 months in patients who had TBI (n = 70) or SAH (n = 32). RESULTS: In TBI, the 3-month evaluation had shown hypopituitarism (H) in 32.8\%. Panhypopituitarism (PH), multiple (MH), and isolated (IH) hypopituitarism had been demonstrated in 5.7, 5.7, and 21.4\%, respectively. The retesting demonstrated some degree of H in 22.7\%. PH, MH, and IH were present in 5.7, 4.2, and 12.8\%, respectively. PH was always confirmed at 12 months, whereas MH and IH were confirmed in 25\% only. In 5.5\% of TBI with no deficit at 3 months, IH was recorded at retesting. In 13.3\% of TBI with IH at 3 months, MH was demonstrated at 12-month retesting. In SAH, the 3-month evaluation had shown H in 46.8\%. MH and IH had been demonstrated in 6.2 and 40.6\%, respectively. The retesting demonstrated H in 37.5\%. MH and IH were present in 6.2 and 31.3\%, respectively. Although no MH was confirmed at 12 months, two patients with IH at 3 months showed MH at retesting; 30.7\% of SAH with IH at 3 months displayed normal pituitary function at retesting. In SAH, normal pituitary function was always confirmed. In TBI and SAH, the most common deficit was always severe GH deficiency. CONCLUSION: There is high risk for H in TBI and SAH patients. Early diagnosis of PH is always confirmed in the long term. Pituitary function in brain-injured patients may improve over time but, although rarely, may also worsen. Thus, brain-injured patients must undergo neuroendocrine follow-up over time

image_1.PDF

Purpose<p>Somatropin [recombinant growth hormone (rGH)] is approved in children and adults for several conditions involving growth disturbances and the corresponding biosimilar is available in Italy since 2006. No population-based data are available on the pattern of rGH use in Italian clinical practice. This study aimed at exploring the pattern of biosimilar and originator rGH use in six Italian centers, where different policy interventions promoted biosimilar use.</p>Methods<p>This population-based, drug-utilization study was conducted in the years 2009–2014, using administrative databases of Umbria, Tuscany, and Lazio Regions and Local Health Units of Caserta, Treviso, and Palermo. Naïve rGH users were characterized, and prevalence of use and discontinuation were assessed over time.</p>Results<p>Among 6,785 patients treated with rGH during the study years, 4,493 (66.2%) were naïve users (males/females = 1.3), mostly affected by GH deficiency. The prevalence of rGH use increased from 2009 to 2010, remaining stable thereafter, but it was heterogeneous across centers (twofold higher prevalence of use in center n.2 than centers n.4 and 1 in 2014). Biosimilar rGH uptake increased over time but was low (7.8% in 2014) and heterogeneous as well. Discontinuation of rGH therapy occurred in 54.0% of naïve users, more frequently in females than males (58.1 vs. 50.9%). During the first year of treatment, discontinuation was frequent (39.9%), but no statistically significant differences were observed in treatment persistence for biosimilar vs. originator rGH (p > 0.05).</p>Conclusion<p>Geographical heterogeneity in the prevalence of rGH use was observed. Similarly, the biosimilar rGH uptake was low and variable across centers. Post-marketing monitoring is required to continuously monitor the benefit-risk profile of rGH, thus guaranteeing greater savings than only promoting lowest cost rGH.</p